Press Release

Nanobodies Market to Grow with a CAGR of 18.23% through 2029

Rising demand for targeted therapeutics is expected to drive the Global Nanobodies Market growth in the forecast period, 2025-2029.


According to TechSci Research report, “Nanobodies Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029”, the Global Nanobodies Market stood at USD 489.21 Million in 2023 and is anticipated to grow with a CAGR of 18.23% in the forecast period, 2025-2029. The rising prevalence of dental disorders, coupled with advancements in dental technology and techniques, has led to an increased number of dental procedures being performed globally. From routine check-ups and preventive care to complex restorative and cosmetic procedures, dental practices are witnessing a surge in patient visits and treatment volumes. This surge in dental procedures translates into a higher demand for disposable dental products used during various stages of treatment, including examination, diagnosis, and treatment delivery. Consequently, the growing number of dental procedures acts as a key driver fueling the growth of the Nanobodies market.

Individuals are increasingly recognizing the significance of oral health and hygiene. Efforts led by governments, dental associations, and oral health advocates have been instrumental in educating the public about the importance of regular dental check-ups, maintaining proper oral hygiene, and preventive measures. This increased awareness has led to a surge in demand for dental services and products, particularly disposable dental items that promote hygienic treatment environments. As a result, the global Nanobodies market is experiencing significant growth driven by this heightened awareness of oral health and hygiene.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Nanobodies Market


The Global Nanobodies market is segmented into type, end user, application, regional distribution, and company.

Based on the type, In 2023, the mono-specific segment emerged as the dominant force in the global Nanobodies market. Multi-specific nanobodies have showcased remarkable adaptability, extending beyond therapeutic applications into diagnostics and research domains. In diagnostics, these nanobodies enable the simultaneous detection of multiple disease biomarkers, enhancing diagnostic accuracy and efficacy. In the research realm, they streamline the investigation of complex biological processes and protein-protein interactions, providing valuable insights into disease mechanisms and potential therapeutic targets. Advancements in biotechnology and protein engineering have driven the development and refinement of innovative platforms for producing and improving multi-specific nanobodies, thereby enhancing their market reach and growth. Collaborative efforts between industry players and academic researchers have further accelerated the expansion of the multi-specific sector, with significant investments in research and development expediting the transition of multi-specific nanobodies from laboratory experimentation to clinical application.

Based on the application, In 2023, the oncology segment emerged as the primary driver of growth in the global Nanobodies market. The oncology field has attracted substantial investment in research and development, particularly focusing on identifying new targets and developing personalized treatment strategies. Collaborations between industry leaders and academic institutions have accelerated the progress of nanobody-based oncology treatments, moving from preclinical studies to clinical trials and eventual commercialization. Oncology remains a significant area of unmet medical need, with the incidence of various cancers rising worldwide. Nanobodies offer distinct advantages in cancer therapy, including precise targeting, improved tissue penetration, and reduced off-target effects, making them promising candidates for precision medicine initiatives. They can be customized to specifically target tumor-associated antigens or pathways, facilitating the development of highly targeted and effective cancer therapies.

Based on the End User, pharmaceutical and biotechnology companies segment emerged as the dominant segment in the global Nanobodies market in 2023. Pharmaceutical and biotechnology companies play a pivotal role in the research, development, and commercialization of nanobody-based therapeutics and diagnostics. These companies possess the resources, expertise, and infrastructure required for conducting large-scale research programs, preclinical studies, and clinical trials aimed at validating the efficacy and safety of nanobody candidates across various disease indications.

The pharmaceutical and biotechnology industry has been actively investing in nanobody research and development, recognizing the potential of nanobodies as a versatile platform for drug discovery and development. With a focus on addressing unmet medical needs and expanding their product pipelines, pharmaceutical and biotechnology companies have been incorporating nanobodies into their research programs and partnering with academic institutions and biotech firms to access novel nanobody technologies and candidates.

North America possesses a strong and well-established biotechnology and pharmaceutical sector, characterized by a notable presence of prominent companies and research organizations specializing in antibody-based therapeutics. North America emerged as the dominant region in the Global Nanobodies Market in 2023, holding the largest market share. North America benefits from a well-established healthcare infrastructure and advanced research ecosystem, comprising academic institutions, research laboratories, and medical centers at the forefront of nanobody research. Collaborative efforts between academia and industry drive innovation and accelerate the pace of nanobody development, positioning North America as a global leader in nanobody research and commercialization.


Major companies operating in Global Nanobodies Market are:

  • Hybrigenics Services
  • Novo Nordisk A/S
  • Merck KGaA
  • Bristol Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Sanofi S.A
  • Beroni Group
  • Shenzhen Kangti Co., Ltd.
  • GlaxoSmithKline plc
  • Sensei Biotherapeutics, Inc


Download Free Sample Report

Customers can also request for 10% free customization on this report


“The global Nanobodies market is poised for significant expansion in the coming years. With the increasing emphasis on infection control and patient safety amidst the ongoing COVID-19 pandemic, the Global Nanobodies Market is expected to witness significant growth in the forecast period. Dental practices worldwide are prioritizing stringent hygiene protocols, driving the demand for disposable dental products to minimize the risk of cross-contamination. Additionally, the adoption of advanced dental technologies and procedures is fueling the need for specialized disposable items tailored to these innovations. said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Nanobodies Market - Global Industry Size, Share, Trends, Opportunity and Forecast, By Type (Mono-Specific, Multi-Specific) By Application (Acquired Thrombotic Thrombocytopenic Purpura (TTP), Respiratory Syncytial Virus Infection, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Oncology, Psoriasis, Chronic Kidney Diseases, Bone Disorders, Others) By End User (Pharmaceutical & Biotechnology Companies, Research Laboratories, and Others), By Region, By Competition, 2019-2029F”, has evaluated the future growth potential of Global Nanobodies Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Nanobodies Market.



TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]


Relevant News